Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk Expects Lower Insulin Prices, Volumes in China to Dent FY22 Global Sales

11/26/2021 | 01:36am EST


ę MT Newswires 2021
All news about NOVO NORDISK A/S
01/20Arecor Therapeutics Initiates Early-Stage Clinical Trial for Insulin Formation
MT
01/14Novo Nordisk Settles Securities Case in Denmark
MT
01/14Novo Nordisk announces settlement of securities lawsuit in Denmark
AQ
01/10Novo Nordisk A/S – Share repurchase programme
AQ
01/062Seventy Bio Working With Novo Nordisk to Develop Potential Gene-Editing Treatment for ..
MT
01/062seventy bio, Inc. Announces Expanded Collaboration Agreement with Novo Nordisk to Cont..
CI
01/06NOVO NORDISK : Deutsche Bank remains Neutral
MD
01/06NOVO NORDISK : Receives a Sell rating from Jefferies
MD
01/05Humanwell Healthcare to Sell Entire RiteDose Stake For $174 Million; Shares Jump 3%
MT
01/04NOVO NORDISK : Gets a Neutral rating from JP Morgan
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 140 B 21 298 M 21 298 M
Net income 2021 47 541 M 7 243 M 7 243 M
Net Debt 2021 1 345 M 205 M 205 M
P/E ratio 2021 30,8x
Yield 2021 1,60%
Capitalization 1 450 B 221 B 221 B
EV / Sales 2021 10,4x
EV / Sales 2022 9,44x
Nbr of Employees 46 982
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Last Close Price 636,50 DKK
Average target price 673,26 DKK
Spread / Average Target 5,78%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S-13.40%220 833
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
ELI LILLY AND COMPANY-11.98%220 420